IBDEI1LZ ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,179,0)
 ;;=MEDICATION ADMIN^7^19
 ;;^UTILITY(U,$J,358.4,180,0)
 ;;=IMMUNIZATION ADMINISTRATION^5^19
 ;;^UTILITY(U,$J,358.4,181,0)
 ;;=IMMUNIZATIONS^6^19
 ;;^UTILITY(U,$J,358.4,182,0)
 ;;=CONTINUOUS GLUCOSE MONITORING^3^19
 ;;^UTILITY(U,$J,358.4,183,0)
 ;;=ANTICOAGULATION^2^20
 ;;^UTILITY(U,$J,358.4,184,0)
 ;;=PAIN^6^20
 ;;^UTILITY(U,$J,358.4,185,0)
 ;;=MENTAL HEALTH^5^20
 ;;^UTILITY(U,$J,358.4,186,0)
 ;;=ENDOCRINE^4^20
 ;;^UTILITY(U,$J,358.4,187,0)
 ;;=CARDIOVASCULAR^3^20
 ;;^UTILITY(U,$J,358.4,188,0)
 ;;=RESPIRATORY^7^20
 ;;^UTILITY(U,$J,358.4,189,0)
 ;;=OTHER^8^20
 ;;^UTILITY(U,$J,358.4,190,0)
 ;;=COMMON DIAGNOSIS^1^20
 ;;^UTILITY(U,$J,358.4,191,0)
 ;;=NEW PATIENT^3^21
 ;;^UTILITY(U,$J,358.4,192,0)
 ;;=ESTABLISHED PATIENT^1^21
 ;;^UTILITY(U,$J,358.4,193,0)
 ;;=CONSULTATIONS^2^21
 ;;^UTILITY(U,$J,358.4,194,0)
 ;;=PREVENTIVE MEDICINE-EST PT^4^21
 ;;^UTILITY(U,$J,358.4,195,0)
 ;;=PREVENTIVE MEDICINE-NEW PT^5^21
 ;;^UTILITY(U,$J,358.4,196,0)
 ;;=RISK FACTOR REDUCTION-GRP^6^21
 ;;^UTILITY(U,$J,358.4,197,0)
 ;;=RISK FACTOR REDUCTION-IND^7^21
 ;;^UTILITY(U,$J,358.4,198,0)
 ;;=OTHER^3^22
 ;;^UTILITY(U,$J,358.4,199,0)
 ;;=EDUCATION/TRAINING^1^22
 ;;^UTILITY(U,$J,358.4,200,0)
 ;;=MEDICAL NUTRITION THERAPY^2^22
 ;;^UTILITY(U,$J,358.4,201,0)
 ;;=WOUND TREATMENT^5^22
 ;;^UTILITY(U,$J,358.4,202,0)
 ;;=PROLONGED SERVICES^4^22
 ;;^UTILITY(U,$J,358.4,203,0)
 ;;=DIABETES^1^23
 ;;^UTILITY(U,$J,358.4,204,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^2^23
 ;;^UTILITY(U,$J,358.4,205,0)
 ;;=NEW PATIENT^3^24
 ;;^UTILITY(U,$J,358.4,206,0)
 ;;=ESTABLISHED PATIENT^2^24
 ;;^UTILITY(U,$J,358.4,207,0)
 ;;=CONSULTATIONS^4^24
 ;;^UTILITY(U,$J,358.4,208,0)
 ;;=PROVIDER WEEKLY VISIT^1^24
 ;;^UTILITY(U,$J,358.4,209,0)
 ;;=ACCESS^5^25
 ;;^UTILITY(U,$J,358.4,210,0)
 ;;=DIALYSIS PROCEDURES^6^25
 ;;^UTILITY(U,$J,358.4,211,0)
 ;;=ESRD HOME SERVICES^7^25
 ;;^UTILITY(U,$J,358.4,212,0)
 ;;=HEMODIALYSIS OVERSIGHT^1^25
 ;;^UTILITY(U,$J,358.4,213,0)
 ;;=LAB^9^25
 ;;^UTILITY(U,$J,358.4,214,0)
 ;;=MEDICATIONS^10^25
 ;;^UTILITY(U,$J,358.4,215,0)
 ;;=MONITORING^11^25
 ;;^UTILITY(U,$J,358.4,216,0)
 ;;=OTHER^12^25
 ;;^UTILITY(U,$J,358.4,217,0)
 ;;=PATIENT EDUCATION/TEACHING^13^25
 ;;^UTILITY(U,$J,358.4,218,0)
 ;;=PATIENT MANAGEMENT^14^25
 ;;^UTILITY(U,$J,358.4,219,0)
 ;;=SUPPLIES^16^25
 ;;^UTILITY(U,$J,358.4,220,0)
 ;;=VACCINATIONS^17^25
 ;;^UTILITY(U,$J,358.4,221,0)
 ;;=DAILY DIALYSIS TXMT^2^25
 ;;^UTILITY(U,$J,358.4,222,0)
 ;;=INPATIENT DIALYSIS^8^25
 ;;^UTILITY(U,$J,358.4,223,0)
 ;;=PERITONEAL DIALYSIS^3^25
 ;;^UTILITY(U,$J,358.4,224,0)
 ;;=TEAM CONFERENCE^4^25
 ;;^UTILITY(U,$J,358.4,225,0)
 ;;=PROLONGED SERVICES^15^25
 ;;^UTILITY(U,$J,358.4,226,0)
 ;;=HEMODIALYSIS-ESRD^14^26
 ;;^UTILITY(U,$J,358.4,227,0)
 ;;=PERITONEAL DIALYSIS ENCOUNTER^23^26
 ;;^UTILITY(U,$J,358.4,228,0)
 ;;=CARDIOLOGY/CARDIORENAL SYNDROME^2^26
 ;;^UTILITY(U,$J,358.4,229,0)
 ;;=COMPLICATIONS/OTHER^4^26
 ;;^UTILITY(U,$J,358.4,230,0)
 ;;=CYSTIC KIDNEY DISEASE^5^26
 ;;^UTILITY(U,$J,358.4,231,0)
 ;;=DIABETES/DIABETIC RENAL DISEASE^6^26
 ;;^UTILITY(U,$J,358.4,232,0)
 ;;=FLUID/ELECTROLYTE DISORDER^8^26
 ;;^UTILITY(U,$J,358.4,233,0)
 ;;=GENERAL SYMPTOMS^9^26
 ;;^UTILITY(U,$J,358.4,234,0)
 ;;=GENITAL/URINARY^10^26
 ;;^UTILITY(U,$J,358.4,235,0)
 ;;=HEMATOLOGY^12^26
 ;;^UTILITY(U,$J,358.4,236,0)
 ;;=HYPERTENSION^15^26
 ;;^UTILITY(U,$J,358.4,237,0)
 ;;=INFECTIOUS DISEASE^16^26
 ;;^UTILITY(U,$J,358.4,238,0)
 ;;=NEPHRITIS GLUMERULONEPHRITIS^18^26
